Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
ophthalmology
Brought to you by:
Biotech
Atsena gene therapy hits safety goals, closes retinal splits
Gene therapy outfit Atsena Therapeutics has debuted data showing its eye disease candidate led to no serious treatment-related adverse events.
Darren Incorvaia
May 19, 2025 12:59pm
Beacon shines a light on positive early data from eye disease ph. 2
May 7, 2025 7:15am
J&J gene therapy fails ph. 3 rare eye disease trial
May 5, 2025 11:33am
Opthea lays off 65% of staff after back-to-back phase 3 flops
Apr 10, 2025 7:52am
Opthea scraps wet AMD program after eye drug loses to Lucentis
Mar 31, 2025 6:55am
Alcon gains majority stake in Aurion after power struggle
Mar 27, 2025 9:23am